EPO and anemia (phenotype): The production of epolones A and B has only been reported once during investigations by OSI Pharmaceuticals for an alternative drug treatment to the use of recombinant human erythropoietin for anemia caused by chronic renal failure, cancer chemotherapy, and a variety of other disease states (Cai et al. 1998).